YOLT-204 in Patients With Hemoglobinopathies

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Hemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease)

Interventions

DRUG

YOLT-204

The intervention group will receive YOLT-204 on day0

Trial Locations (1)

Guangzhou women and children's medical center, Guangzhou

All Listed Sponsors

lead

Guangzhou Women and Children's Medical Center

OTHER